VBI Vaccines

164 articles about VBI Vaccines

• VBI Vaccines Reports First Quarter 2023 Financial Results

  5/15/2023

  VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial results for the quarter ended March 31, 2023.

• VBI Vaccines Appoints Vaughn Himes to Board of Directors

  4/25/2023

  VBI Vaccines Inc. today announced that Vaughn B. Himes, Ph.D., Chief Technical Officer of Seagen Inc., has joined VBI’s Board of Directors.

• VBI Vaccines Announces Increased Focus on Hepatitis B, Organizational Changes, and Reverse Stock Split

  4/4/2023

  VBI Vaccines Inc. announced plans to focus the Company’s efforts on the fight against hepatitis B, concentrating on broadening access to VBI’s FDA-approved 3-antigen HBV vaccine for adults, PreHevbrio™ [Hepatitis B Vaccine ], and advancing its HBV immunotherapeutic candidate, VBI-2601, which has the potential to be part of a functional cure regimen for chronic HBV patients.

• VBI Vaccines Reports Full Year 2022 Financial Results

  3/13/2023

  VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial results for the year ended December 31, 2022.

• VBI Vaccines to Discuss Progress in Hepatitis B Portfolio in Analyst-Led Fireside Chat

  2/23/2023

  VBI Vaccines Inc. today announced that Jeff Baxter, VBI’s President and CEO, and David E. Anderson, VBI’s Chief Scientific Officer, will discuss the company’s hepatitis B (HBV) portfolio with covering analyst, Steven Seedhouse, Ph.D., from Raymond James & Associates, Inc.

• VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B

  2/15/2023

  VBI Vaccines Inc. (Nasdaq: VBIV) (VBI) today announced interim data from the Phase 2 study evaluating the combination of VBI-2601 (BRII-179), VBI’s HBV immunotherapeutic candidate, and BRII-835 (VIR-2218), an HBV-targeting siRNA candidate, in chronically infected HBV patients.

• VBI Vaccines Announces Health Canada Approval for PreHevbrio™ for the Prevention of Hepatitis B in Adults

  12/8/2022

  VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Health Canada has approved PreHevbrio™ [3-antigen Hepatitis B Vaccine (Recombinant)] for active immunization against infection caused by all known subtypes of hepatitis B (HBV) virus in adults 18 years of age and older.

• VBI Vaccines Presents Additional Phase 1/2a Data from VBI-1901 in Recurrent GBM at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting

  11/22/2022

  VBI Vaccines Inc. today announced that additional biomarker data from the Phase 1/2a study of VBI-1901, the Company’s cancer vaccine immunotherapeutic candidate in recurrent glioblastoma (GBM), were presented at the 27th Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO), on Friday, November 18, 2022.

• VBI Vaccines to Participate in Upcoming Investor Conferences - November 14, 2022

  11/14/2022

  VBI Vaccines Inc. today announced that members of the management team will participate in analyst-led fireside chats at the following investor conferences.

• VBI Vaccines Announces Presentation of Data from Ongoing Phase 2a Study of VBI-1901 at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting

  11/11/2022

  VBI Vaccines Inc. today announced that its abstract highlighting data from the ongoing Phase 2a study of VBI-1901, the Company’s cancer vaccine immunotherapeutic candidate in recurrent glioblastoma (GBM), was accepted for poster presentation at the 27th Annual Meeting and Education Day of the Society for Neuro-Oncology Annual Meeting.

• VBI Vaccines Reports Third Quarter 2022 Financial Results and Provides Corporate Update

  11/10/2022

  VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced financial results for the third quarter ended September 30, 2022, and provided a corporate update.

• VBI Vaccines to Participate in H.C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference

  10/17/2022

  VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Jeff Baxter, VBI’s President and CEO, and David E. Anderson, Ph.D., VBI’s Chief Scientific Officer, will participate in an analyst-led fireside chat at the H.C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference.

• VBI Vaccines and Agenus Announce Collaboration to Evaluate VBI-1901 in Combination with Anti-PD-1 Balstilimab in a Phase 2 Study in Primary Glioblastoma Patients

  10/12/2022

  VBI Vaccines Inc. and Agenus announced a collaboration to evaluate the combination of VBI-1901, VBI’s cancer vaccine immunotherapeutic, and balstilimab, Agenus’ monoclonal antibody targeting the programmed death receptor-1 protein, in primary glioblastoma patients as part of the adaptive platform trial, INSIGhT.

• VBI Vaccines Announces Initiation of Phase 1 Study of Multivalent Coronavirus Vaccine Candidate, VBI-2901

  9/29/2022

  VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the initiation of enrollment in the Phase 1 clinical study of VBI-2901, a multivalent enveloped virus-like particle (eVLP) coronavirus vaccine candidate.

• VBI Vaccines Announces Presentation of Physician-Initiated Compassionate Use Data of its 3-Antigen Hepatitis B Vaccine at the 2022 International HBV Meeting

  9/21/2022

  VBI Vaccines Inc. today announced that data from the physician-initiated compassionate use of VBI’s 3-antigen hepatitis B vaccine in four adults chronically infected with hepatitis B virus (HBV) were presented in a poster session at the 2022 International HBV Meeting in Paris, France.

• VBI Vaccines Secures $100 Million Debt Facility From K2 HealthVentures

  9/15/2022

  VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced it has entered into a refinanced and upsized debt facility of up to $100 million with its existing lender, K2 HealthVentures (K2HV), a healthcare-focused specialty finance company.

• Valneva and VBI Vaccines Announce European Partnership for Marketing and Distribution of PreHevbri®

  9/8/2022

  Valneva SE and VBI Vaccines Inc. announced a partnership in select European markets for the marketing and distribution of PreHevbri® [Hepatitis B vaccine ], the only 3-antigen hepatitis B vaccine approved in Europe.

• VBI Vaccines Reports Second Quarter 2022 Financial Results and Provides Corporate Update

  8/8/2022

  VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced financial results for the second quarter ending June 30, 2022 and provided a corporate update.

• VBI Vaccines Announces Appointment of John Dillman as Chief Commercial Officer

  7/12/2022

  VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that John Dillman has been appointed as the Company’s Chief Commercial Officer.

• VBI Vaccines Announces New Long-Term Follow-Up Clinical Data for its 3-Antigen Adult Hepatitis B Vaccine Presented at EASL 2022

  6/28/2022

  VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that new data from a follow-up analysis of a subset of participants from the pivotal Phase 3 study (PROTECT) of the Company’s 3-antigen prophylactic hepatitis B (HBV) vaccine.